Home/Filings/4/0001213900-22-028975
4//SEC Filing

McGovern Jr. Donald A. 4

Accession 0001213900-22-028975

CIK 0001690080other

Filed

May 22, 8:00 PM ET

Accepted

May 23, 4:31 PM ET

Size

10.3 KB

Accession

0001213900-22-028975

Insider Transaction Report

Form 4
Period: 2022-05-19
Transactions
  • Award

    Common Stock

    2022-05-19$1.36/sh+12,409$16,87650,587 total
  • Award

    Non-Qualified Stock Option (right to buy)

    2022-05-19+15,00015,000 total
    Exercise: $1.36Exp: 2032-05-19Common Stock (15,000 underlying)
  • Award

    Non-Qualified Stock Option (right to buy)

    2022-05-19+134,121134,121 total
    Exercise: $1.36From: 2022-05-19Exp: 2032-05-19Common Stock (134,121 underlying)
Footnotes (4)
  • [F1]Issued in consideration for serving on the Board of Directors, as Lead Director, Chairman of the Audit Committee, and as a Member of the Compensation Committee and of the Risk, Safety and Regulatory Committee of the Board of Directors, for the quarter ended March 31, 2022. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.
  • [F2]Granted in consideration for services rendered and to be rendered as a member of the Board of Directors. Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.
  • [F3]The Options vest at the rate of 1/39th of such options ratably on a monthly basis over the following 39 months following the grant date, on the last day of each calendar month (beginning on May 31, 2022), subject to the holder's continued service to the Company.
  • [F4]Granted in consideration for serving as Lead Director of the Company during 2021 and 2022 (to date). Granted under the registrant's 2020 Omnibus Incentive Plan. Exempt pursuant to Rule 16b-3.

Documents

1 file

Issuer

180 Life Sciences Corp.

CIK 0001690080

Entity typeother

Related Parties

1
  • filerCIK 0001706276

Filing Metadata

Form type
4
Filed
May 22, 8:00 PM ET
Accepted
May 23, 4:31 PM ET
Size
10.3 KB